文献速递类风湿关节炎系统性红斑狼疮

IRAK4抑制剂PF-06650833在风湿病临床前模型及随机临床试验中阻断炎症

The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.
PubMed 文献 · Arthritis Rheumatol · 2021-11-01

该研究在体外、体内及人体临床试验中评估了选择性IRAK4抑制剂PF-06650833对自身免疫病理的作用。体外实验显示PF-06650833抑制了RA和SLE患者血浆刺激的原代细胞炎症反应;动物模型显示其降低狼疮小鼠自身抗体水平并保护大鼠CIA;I期临床试验中,PF-06650833降低了健康志愿者全血干扰素基因特征表达。结论为抑制IRAK4激酶活性可降低人体炎症标志物水平,支持IRAK4抑制剂用于风湿病适应症的临床开发。

要点

  • PF-06650833在体外抑制RA和SLE相关刺激诱导的人原代细胞炎症反应。
  • PF-06650833在狼疮小鼠模型中降低循环自身抗体,在大鼠CIA模型中起保护作用。
  • I期试验中PF-06650833降低健康志愿者全血干扰素基因特征表达,显示人体药理学作用。

核心结论

  • 抑制IRAK4激酶活性可降低人体炎症标志物水平,支持IRAK4抑制剂用于风湿病适应症的临床开发。

研究设计与样本

  • 体外使用抗环瓜氨酸蛋白抗体免疫复合物刺激的原代人巨噬细胞、TLR配体刺激的RA成纤维样滑膜细胞及人原代细胞共培养模拟RA病理。
  • 体外使用TLR配体和SLE患者免疫复合物刺激的人中性粒细胞、树突状细胞、B细胞和外周血单核细胞模拟SLE病理。
  • 体内使用大鼠胶原诱导性关节炎模型及小鼠降植烷诱导和MRL/lpr狼疮模型评估PF-06650833。
  • 利用I期多次递增剂量临床试验(NCT02485769)健康志愿者全血RNA测序数据测试人体药理学。

主要发现

  • 体外PF-06650833抑制了RA和SLE患者血浆产生的生理相关刺激引起的人原代细胞炎症反应。
  • 体内PF-06650833降低降植烷诱导和MRL/lpr狼疮小鼠模型的循环自身抗体水平,并保护大鼠免于CIA。
  • I期临床试验中PF-06650833通过降低健康志愿者全血干扰素基因特征表达显示出与SLE相关的体内药理学作用。

临床怎么用

  • IRAK4抑制剂PF-06650833在临床前和人体早期试验中显示抗炎作用,支持其作为风湿病(如RA、SLE)候选药物的进一步临床开发。

局限性

  • 人体药理学数据来自健康志愿者的I期临床试验,而非风湿病患者。
  • 临床前模型结果需在患者中进一步验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the role of PF-06650833, a highly potent and selective small-molecule inhibitor of interleukin-1-associated kinase 4 (IRAK4), in autoimmune pathophysiology in vitro, in vivo, and in the clinical setting. METHODS: Rheumatoid arthritis (RA) inflammatory pathophysiology was modeled in vitro through 1) stimulation of primary human macrophages with anti-citrullinated protein antibody immune complexes (ICs), 2) RA fibroblast-like synoviocyte (FLS) cultures stimulated with Toll-like receptor (TLR) ligands, as well as 3) additional human primary cell cocultures exposed to inflammatory stimuli. Systemic lupus erythematosus (SLE) pathophysiology was simulated in human neutrophils, dendritic cells, B cells, and peripheral blood mononuclear cells stimulated with TLR ligands and SLE patient ICs. PF-06650833 was evaluated in vivo in the rat collagen-induced arthritis (CIA) model and the mouse pristane-induced and MRL/lpr models of lupus. Finally, RNA sequencing data generated with whole blood samples from a phase I multiple-ascending-dose clinical trial of PF-06650833 were used to test in vivo human pharmacology. RESULTS: In vitro, PF-06650833 inhibited human primary cell inflammatory responses to physiologically relevant stimuli generated with RA and SLE patient plasma. In vivo, PF-06650833 reduced circulating autoantibody levels in the pristane-induced and MRL/lpr murine models of lupus and protected against CIA in rats. In a phase I clinical trial (NCT02485769), PF-06650833 demonstrated in vivo pharmacologic action pertinent to SLE by reducing whole blood interferon gene signature expression in healthy volunteers. CONCLUSION: These data demonstrate that inhibition of IRAK4 kinase activity can reduce levels of inflammation markers in humans and provide confidence in the rationale for clinical development of IRAK4 inhibitors for rheumatologic indications.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Winkler A, Sun W, De S, et al. The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial. Arthritis Rheumatol. 2021. PMID: 34423919. doi:10.1002/art.41953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。